At the marketing board level, they are looking at ways of doing this that, perhaps, were not on the table three, four or five years ago.

28. Encourages taking immediate action to create a financial environment for research into the prevention of further outbreaks, and to coordinate and strengthen medical research and the production of effective medicines, clinical tests and policies, not only against Ebola but also against certain other epidemic-prone, life-threatening infectious diseases that cause a high number of deaths in Africa, and to publish the data regarding vaccine safety and effectiveness; stresses the necessity of not withdrawing from research efforts, giv ...[+++]en the need for continuous control of the epidemic, taking care to secure ethical conditions for the trials by means of informed prior consent of the patients who take part in the trials, transparency in the clinical data resulting from this research and effective access to these vaccines and treatments by the populations concerned (qualified staff and adequate infrastructure for care delivery, with the price not exceeding the real cost of production); expects the grant agreements of the Ebola+ programme to be made public with regard to their conditions and award procedures;

– Mr President, I think this report is going to be a test case whether the European Parliament has to serve the interests of the citizens first – and citizens are really worried – or yield to the pressure of big companies, a pressure that has become really embarrassing.

Research will focus on: developing promising candidate interventions (vaccines, therapies and HIV microbicides) against the target diseases by sponsoring research over the full spectrum from basic molecular research, taking advantage of microbial genomics, through to pre-clinical testing and proof-of-principle; establishing a clinical trials programme to unite and support Europe"s clinical trial activities specifically targeted at interventions for use in developing countries; establishing an AIDS Therapy Trials Network in Europe to improve the coherence and complementarity of clinical trials of AIDS therapies for European use.

Research will focus on: developing promising candidate interventions (vaccines, therapies and HIV microbicides and evaluation criteria on the various interventions and the effects on public health ) against the target diseases by sponsoring research over the full spectrum from basic molecular research, taking advantage of microbial genomics, through to pre-clinical testing and proof-of-principle; establishing a clinical trials programme to unite and support Europe"s clinical trial activities specifically targeted at interventions for use in developing countries; establishing an AIDS Prevention (vaccines) and Therapy Trials Network in Europe to improve the coherence and complem ...[+++]entarity of clinical trials of AIDS therapies for European use.

Research will focus on: developing promising candidate interventions (vaccines, therapies and HIV microbicides and evaluation criteria on the various interventions and public health impact) against the target diseases by sponsoring research over the full spectrum from basic molecular research, taking advantage of microbial genomics, through to pre-clinical testing and proof-of-principle; establishing a clinical trials programme to unite and support Europe’s clinical trial activities specifically targeted at interventions for use in developing countries; establishing an AIDS Prevention (vaccines) and Therapy Trials Network in Europe to improve the coherence and complementarity ...[+++]of clinical trials of AIDS therapies for European use.